PHARMA NEWS

  • Lumis Global Pharmaceuticals, a Wuhan, China-based manufacturer of active pharmaceutical ingredients (APIs), has received ...

  • Badrivishal Chemicals & Pharmaceuticals, a Talegaon Dabhade, India-headquartered manufacturer of active pharmaceutical ingredients ...

  • The US Food and Drug Administration has recently issued Warning Letters to two India-based and one China-based active pharmaceutical ...

  • Sun Pharmaceutical Industries, a Mumbai, India-headquartered specialty generic pharmaceutical company, has been informed ...

  • Mayne Buys Transdermal Drug Rights

    Mayne Pharma, a Salisbury South, Australia-headquartered contract development and manufacturing organization and drug delivery ...

  • The Food and Drug Administration (FDA) is considering establishing a new Office of Patient Affairs to enhance future patient ...

  • Pfizer has issued a voluntary Class III recall for 582,165 vials of the gastrointestinal drug, Protonix (pantoprazole sodium) ...

  • Allergan in CRISPR Eye-Drug Pact

    Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, has entered into a strategic research ...

  • Takeda Partners on Biotech Venture

    Takeda Pharmaceutical has partnered with Innovation Network Corporation of Japan (INCJ), a Tokyo-headquartered public-private ...

  • Daiichi Sankyo in Pain-Drug Deal

    Daiichi Sankyo has entered into a drug discovery and licensing agreement with Heptares Therapeutics Limited, a Hertfordshire, ...

  • Amo Pharma Partners in Rare Diseases

    Amo Pharma, a London-based privately held biopharmaceutical company, has entered into a collaboration agreement with Ranedis ...

  • Megafine Pharma, a Mumbai, India-headquartered manufacturer of active pharmaceutical ingredients (APIs) and advanced intermediates, ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Novartis and Pfizer. ...

  • The Pharmaceutical Inspection Co-operation Scheme (PIC/S), a non-binding, informal co-operative arrangement between regulatory ...

  • Mylan has agreed to the terms of a global settlement with Roche and its subsidiary, Genentech, in relation to patents for ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Dr. Reddys Laboratories is addressing a violations report issued by the US Food and Drug Administration (FDA) for Dr. Reddys ...

  • The US Food and Drug Administration (FDA) has issued a Warning Letter dated February 17, 2017 to Morton Grove Pharmaceuticals, ...

  • President Donald Trump has announced his intent to nominate Scott Gottlieb, MD, as Commissioner of Food and Drugs at the ...

  • Apotex Inc., a Weston, Florida-headquartered, Canadian-owned generic pharmaceutical company, plans to invest $184 million ...

  • BeiGene, a Beijing, China-based clinical-stage, research-based biotechnology company, has formed a joint venture with the ...

  • GlaxoSmithKline (GSK) has decided to transfer its manufacturing operation in Costa Rica after reviewing its global manufacturing ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Vertex to Buy Cystic Fibrosis Drug

    Vertex Pharmaceuticals, a Boston, Massachusetts-headquartered biotechnology company, has agreed to acquire a cystic fibrosis ...

  • The Ministry of Health (MoH) of the Russian Federation has granted marketing authorization to Biocad, a St. Petersburg, ...

  • Sanofi and its vaccines global business unit, Sanofi Pasteur, have entered into an agreement with MedImmune, the global ...

  • Otsuka Pharmaceutical has agreed to acquire Neurovance, a Cambridge, Massachusetts-headquartered clinical-stage pharmaceutical ...

  • Merck KGaAs allergy business, Allergopharma, has opened a new EUR 42 million ($45 million) biopharmaceutical production ...

  • GlaxoSmithKline (GSK) has completed the previously announced divestiture of its anesthesia portfolio to Aspen Pharma, a ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Perrigo and Teva. ...

  • Ligand Pharmaceuticals, a San Diego-based biopharmaceutical company, has expanded its license with Sermonix Pharmaceuticals, ...

  • Astellas Pharma has entered into an exclusive worldwide license agreement with Affinivax, a Cambridge, Massachusetts-headquartered ...

  • Boehringer Ingelheim (BI) has formed a new multi-year collaboration with Vanderbilt University, based in Nashville, Tennessee, ...

  • Boehringer Ingelheim (BI) has invested EUR 52 million ($55 million) in a new building that recently opened at the Research ...

  • BMS Invests in Precision Medicine

    Bristol-Myers Squibb (BMS) has made an equity investment in and plans to form a research collaboration with Grail, a Menlo ...

  • Merck & Co. has reported that it is taking a $2.9-billion impairment charge on a hepatitis C drug candidate that the company ...

  • Novo Nordisk has appointed Doug Langa as senior vice president, head of North America Operations and president of Novo Nordisk ...

  • Eli Lilly and Company has completed its previously announced $960-million acquisition of CoLucid Pharmaceuticals, a Cambridge, ...

  • Perrigo has announced a global workforce reduction of 750 employees, or 14% of the companys global workforce, as part of ...

  • Endo International has reported $3.5-billion asset impairment charges in the fourth-quarter of 2016 relating to pricing ...

  • Endo Recalls One Lot of ED Drug

    Endo International plc, a specialty and generics drug company, reports that one of its operating companies, Endo Pharmaceuticals ...

  • Astellas Pharma has agreed to provide exclusive distribution and promotion rights in Japan to Kyowa Pharmaceutical Industry, ...

  • Baxter International has entered into a strategic partnership with ScinoPharm Taiwan, a Taiwan-based provider of process ...

  • Roche in Combo Cancer Therapy Deal

    Roche has formed a collaboration with Exelixis, a South San Francisco, California-headquartered biopharmaceutical company, ...

  • Bristol-Myers Squibb (BMS) has entered into a clinical development collaboration with, to evaluate Exelixis Cabometyx (cabozantinib), ...

  • Advaxis, a Princeton, New Jersey-based clinical-stage biotechnology company, has granted a license to Sellas, a Hamilton, ...

  • Sanofi and Lonza have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility ...

  • Perrigo has agreed to divest its rights to the royalty stream from global net sales of Tysabri (natalizumab), Biogens multiple ...

  • Hikma Pharmaceuticals, an Amman, Jordan-based pharmaceutical company, has signed an exclusive licensing and distribution ...

  • Valeant Pharmaceuticals has entered into a three-year agreement through its Ireland subsidiary with Swedish Orphan Biovitrum ...

  • Valeant Pharmaceuticals wholly owned subsidiary, Obagi Medical Products, an Irvine, California-based professional skin care ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from AstraZeneca, Amgen, ...

  • Stada Arzneimittel AG, a Bad Vilbel, Germany-headquartered pharmaceutical company, has received a bid for acquisition of ...

  • Celltrion Healthcare, the marketing, sales, and distribution arm of Celltrion, an Incheon, South Korea-based pharmaceutical ...

  • Editor's Note: The Warning Letter issued to Pfizer, dated February 14, 2017, has now been posted on the US Food and Drug ...

  • Pharmaceutical companies joined other US-based companies in sending a letter to US Congressional leadership in support of ...

  • Takeda to Establish Joint Venture

    Takeda Pharmaceutical has partnered with PRA Health Sciences, a Raleigh, North Carolina-based contract research organization, ...

  • Eisai has entered into a marketing and distribution agreement in China with Orion Corporation, an Espoo, Finland-headquartered, ...

  • Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), has expanded its collaboration ...

  • Gilead Sells Anti-Addiction Drug

    Gilead Sciences has agreed to sell its aldehyde dehydrogenase 2 (ALDH2) inhibitor, a drug candidate with the potential to ...

  • Swedish Orphan Biovitrum (Sobi), a Stockholm, Sweden-headquartered specialty healthcare company, has elected to add a product ...

  • Dr. Reddys Laboratories has expanded its commercial operations in Europe with the introduction of its generic drug portfolio ...

  • Actavis Inc,, part of Teva Pharmaceutical Industries, has issued a Class II voluntarily recall of 499,320 units of glipizide ...

  • The US Food and Drug Administration (FDA) has posted a Warning Letter to Sato Pharmaceutical, a Tokyo-headquartered manufacturer ...

  • Amgen and Pfizer Lead Pipeline News

    A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from AstraZeneca, Perrigo, ...

  • AstraZeneca and its partner, Valeant Pharmaceuticals, have received US Food and Drug Administration approval for Siliq (brodalumab) ...

  • AstraZeneca has agreed to license the commercial rights to Zoladex (goserelin acetate implant), a cancer drug, in the US ...

  • Valeant Pharmaceuticals International has entered into an exclusive, worldwide licensing agreement with EyeGate Pharmaceuticals, ...

  • Gilead Sciences has agreed to purchase a Rare Pediatric Disease Priority Review Voucher (PRV) from Sarepta Therapeutics, ...

  • GEA, a Dusseldorf, Germany-headquartered engineering group, has been selected by Hanmi Pharmaceutical, a Seoul, South Korea-headquartered ...

  • Lannett, a Philadelphia-headquartered generic drug manufacturer, has announced that it will invest $50 million to expand ...

  • The US Food and Drug Administration (FDA) has accepted a biologics license application from Mylan and its partner, Biocon, ...

  • Takeda Pharmaceutical has completed its previously announced acquisition of Ariad Pharmaceuticals, headquartered in Cambridge, ...

  • West-Ward Pharmaceuticals, a Columbus, Ohio-based generic prescription medication provider and a wholly owned subsidiary ...

  • Aurobindo Pharma, a Hyderabad, India-headquartered generics and active pharmaceutical ingredients manufacturer, has acquired ...

  • Seattle Genetics, a Bothell, Washington-headquartered biotechnology company, has entered into a development and license ...

  • Neurocrine Biosciences, a San Diego-based biopharmaceutical company focused on neurological and endocrine diseases, has ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Amgen and Lilly. ...

  • Daiichi Sankyo Group has decided to close its Japanese research subsidiary, Asubio Pharma, based in Kobe, Japan, by the ...

  • Allergan has agreed to acquire Zeltiq Aesthetics, a Pleasanton, California-headquartered medical technology company that ...

  • Janssen Pharmaceutica, one of the Janssen Pharmaceutical companies of Johnson & Johnson, has entered into an exclusive agreement ...

  • Astellas Pharma has announced changes in its top management structure, effective on April 1, 2017 and has formed a division, ...

  • Pfizer has announced that it will close its Adelaide, Australia manufacturing plant, which produces the active ingredient ...

  • Incyte, a Wilmington, Delaware-based biopharmaceutical company, and Agenus, a Lexington, Massachusetts-based clinical-stage ...

  • The United States Court of Appeals for the Federal Circuit has stayed a permanent injunction for Sanofi's and Regeneron ...

  • The US Federal Trade Commission (FTC) has filed a civil action in federal district court against Shire ViroPharma, a wholly ...

  • Mallinckrodt, a specialty pharmaceutical company has agreed to sell its intrathecal therapy business to Piramal Critical ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from BMS, Endo, Merck ...

  • Novartis has withdrawn its marketing authorization application (MMA) with the European Medicines Agency (EMA) for its biosimilar ...

  • Allergan has successfully completed the acquisition of LifeCell Corporation, the regenerative medicines business of Acelity, ...

  • The Japan Intellectual Property High Court has ruled in favor of Eli Lilly and Company and has confirmed the decisions of ...

  • Astellas Pharma has executed a license agreement for an exclusive worldwide license to an ear-care program with Auration ...

  • Portola Pharmaceuticals, a South San Francisco, California-based biopharmaceutical company focused on the field of thrombosis ...

  • Eli Lilly and Company plans to reduce it global research and development (R&D) workforce by 200 positions as part of a voluntary ...

  • Teva Appoints Interim CEO

    Teva Pharmaceutical Industries has appointed Dr. Yitzhak Peterburg as interim president and chief executive officer (CEO), ...

  • Strides Shasun, a Bangalore, India-headquartered pharmaceutical company, has announced a company restructuring that will ...

  • Kyowa Hakko Kirin, a Japan-based pharmaceutical company, has established a subsidiary, Kirin Frontier Co., which will seek ...

  • The European Patent Office (EPO) has upheld a decision that found a patent for Bristol-Myers Squibbs (BMS) anti-cancer drug, ...

  • Biogen has completed the separation of its global hemophilia business into a spin-out company, Bioverativ, which now stands ...

  • Sanofi Pasteur, the vaccines unit of Sanofi, has agreed to pay $61.5 million to settle a class-action lawsuit involving ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Allergan, AstraZeneca, ...

  • Teva Pharmaceutical Industries says it plans to appeal a recent court ruling that invalidated four of its patents for Copaxone ...

  • Lek, a Sandoz company and part of Novartis, is investing to expand production of broad-spectrum antibiotics at Novartis ...

  • US President Donald Trump met with pharmaceutical industry executives and representatives from Pharmaceutical Research and ...

  • Eli Lilly and Company has terminated its $570-million collaboration research and license agreement with Adocia, a Lyon, ...

  • H. Lundbeck, a Valby, Denmark-based pharmaceutical company specializing in psychiatric and neurological disorders, has formed ...

  • Immune Pharmaceuticals, a New York-headquartered clinical-stage biopharmaceutical company focused on inflammatory diseases ...

  • Beximco Pharmaceuticals, a Dhaka, Bangladesh-headquartered manufacturer of generic pharmaceuticals and active pharmaceutical ...

  • Zymeworks Opens R&D Lab for ADCs

    Zymeworks, a Vancouver, Canada-headquartered clinical-stage biopharmaceutical company, has opened a new 10,000-square-foot ...

  • Biocon, a Bangalore, India-headquartered biopharmaceuticals company, has been awarded a three-year, Malaysia ringgit 300 ...

  • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive ...

  • Novo Nordisk has formed a research collaboration with the University of Oxford in the UK for the development of Type 2 ...

  • Incyte, a Wilmington, Delaware-based biopharmaceutical company, has formed a collaboration and license agreement with Calithera ...

  • Mylan has issued a voluntarily Class II recall of four dosage forms of temozolomide capsules, a chemotherapy brain-tumor ...

  • Pfizer Leads Pipeline News

    A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Adma Biologics, a Ramsey, New Jersey-based late-stage biopharmaceutical company focused on specialty plasma-based biologics, ...

  • Takeda Pharmaceutical has signed an exclusive licensing agreement with Exelixis, a South San Francisco, California-based ...

  • Johnson & Johnson (J&J) has agreed to acquire Actelion, an Allschwil, Switzerland-based biopharmaceutical company, in a ...

  • Endo International has initiated a restructuring program that primarily impacts the companys corporate functions and branded ...

  • Celgene, a Summit, New Jersey-based biopharmaceutical company, has agreed to acquire Delinia, a privately held biotechnology ...

  • Bristol-Myers Squibb (BMS) and its partner, Ono Pharmaceutical Company, headquartered in Osaka, Japan, have signed a global ...

  • Takeda Pharmaceutical has formed a global collaboration with Ovid Therapeutics, a privately held New York-based biopharmaceutical ...

  • Takeda Pharmaceutical has begun a cash tender offer, through its wholly owned indirect subsidiary, Kiku Merger, for all ...

  • Perrigo has issued a voluntary Class II recall of 162,534 tubes of clindamycin phosphate and benzoyl peroxide gel, a prescription ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from AbbVie, Allergan, ...

  • Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company, has entered into an agreement with ...

  • Merck KGaA has signed a collaboration and license agreement with Domain Therapeutics, a biopharmaceutical company headquartered ...

  • Both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have accepted for review Boehringer ...

  • Valeant Pharmaceuticals has agreed to sell all of the outstanding equity interests in Dendreon Pharmaceuticals, headquartered ...

  • The Bill & Melinda Gates Foundation, the Wellcome Trust, and the governments of Germany, Japan, and Norway have pledged ...

  • Generex Biotechnology, based in Toronto, has signed a letter of intent to acquire a controlling equity interest in Emmaus ...

  • Eli Lilly and Company plans to cut 485 sales positions across its operations in the US, including its US Bio-Medicines Business ...

  • Endo International, a specialty pharmaceutical and generic-drug company, and the US Federal Trade Commission (FTC) have ...

  • Eli Lilly and Company has agreed to acquire CoLucid Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical ...

  • GlaxoSmithKline (GSK) has appointed Luke Miels as the new president of its Global Pharmaceuticals business with the upcoming ...

  • Eisai, Chugai Pharmaceutical, and Roche have agreed that Eisai will acquire the manufacturing rights in Japan for the active ...

  • Astellas Terminates Vaccines Pact

    Astellas Pharma has terminated an agreement that was executed in September 2010 between it and UMN Pharma, a pharmaceutical ...

  • Takeda Partners in ADCs

    Takeda Pharmaceutical has entered into a research licensing agreement with LegoChem Biosciences (LCB), a biopharmaceutical ...

  • Takeda Pharmaceutical has formed a five-year collaboration with Maverick Therapeutics, a Brisbane, California-based private ...

  • Amgen in Anemia Drug Supply Pact

    Amgen has entered into a new six-year sourcing and supply agreement with DaVita, a kidney-care company based in Denver, ...

  • Eli Lilly and Company has expanded an existing immuno-oncology collaboration with Merck & Co., through a subsidiary, to ...

  • Merck KGaA has entered into a licensing agreement with Vertex Pharmaceuticals, a Boston-based biotechnology company, for ...

  • A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring ...

  • Perrigo Changes Reporting Structure

    Perrigo has changed its reporting segments to better align with the company's organizational structure. Beginning with the ...

  • Gilead Leads Drug Approval News

    A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Gilead. Editor's ...

  • Eli Lilly and Company has received a favorable ruling from the US Court of Appeals for the Federal Circuit, which upheld ...

  • Merck KGaA Partners in Big Data

    Merck KGaA has partnered with Palantir Technologies, a developer of data integration and analysis software headquartered ...

  • AbbVie has formed a collaboration with Zebra Biologics, an emerging preclinical-stage biotechnology company headquartered ...

  • Aurobindo Pharma, a generics and active pharmaceutical ingredients (API) manufacturer headquartered in Hyderabad, India ...

  • Aerie Pharmaceuticals, an Irvine, California-headquartered clinical-stage pharmaceutical company focused on glaucoma and ...

  • Merck KGaA has appointed Joachim Christ as its new chief procurement officer (CPO), succeeding Friedhelm Felten in that ...

  • Biogen has agreed to a settlement and license agreement with Forward Pharma, a Copenhagen, Denmark-headquartered biopharmaceutical ...

  • Pfizer Saudi Limited, a subsidiary of Pfizer, has opened a manufacturing facility in King Abdullah Economic City (KAEC), ...

  • Amgen has boosted its pain-drug portfolio by signing a deal with SiteOne Therapeutics, a pharmaceutical company headquartered ...

  • Amgen has been granted a permanent injunction by the United States District Court in Delaware that prohibits Sanofi and ...

  • Sanofi has extended its cardiomyopathy research collaboration with MyoKardia, a clinical-stage biopharmaceutical company ...

  • BMS, Janssen in Immunotherapy Pact

    Bristol-Myers Squibb (BMS) has formed a new clinical research collaboration with Janssen Biotech, a Johnson & Johnson company, ...

  • Novartis has formed a collaboration and option agreement with Ionis Pharmaceuticals, a Carlsbad, California-based pharmaceutical ...

  • Takeda Pharmaceutical has entered into an agreement with PvP Biologics, a San Diego-headquartered biopharmaceutical company, ...

  • Pfizer has formed a collaboration with AbCellera Biologics, a privately held biotechnology company headquartered in Vancouver, ...

  • Eisai, with its US pharmaceutical subsidiary Eisai Inc., has revised an agreement with Arena Pharmaceuticals, a San Diego-based ...

  • AstraZeneca has entered into an agreement with APT Therapeutics, a privately held biopharmaceutical company headquartered ...

  • Shire has sold its MRT platform, which is an mRNA-based therapy platform developed by its subsidiaries, to RaNA Therapeutics, ...

  • Takeda Pharmaceutical has agreed to acquire Ariad Pharmaceuticals, headquartered in Cambridge, Massachusetts, for $24 per ...

  • Merrimack Pharmaceuticals, headquartered in Cambridge, Massachusetts, has agreed to sell two oncology drugs to Ipsen, a ...

  • EMD Serono, the biopharmaceutical business of Merck KGaA, has formed a three-year strategic collaboration with The University ...

  • AbbVie has formed four new collaborations and investments with healthcare innovators to advance early-stage research in ...

  • Sanofi has signed an agreement with ImmuNext, a biopharmaceutical company headquartered in Lebanon, New Hampshire, to develop ...

  • Allergan has entered two deals, one for gastrointestinal (GI) drug development and another for development of drugs to treat ...

  • Amgen has formed a research collaboration and license agreement with Immatics Biotechnologies, a clinical-stage biopharmaceutical ...

  • Celgene Switzerland, an affiliate of Celgene, has formed a research collaboration with Anokion, a privately held biopharmaceutical ...

  • Mylan to Acquire OTC Cold Remedy

    Mylan has agreed to acquire global rights to the Cold-EEZE brand cold remedy line from ProPhase Labs, a Doylsetown, Pennsylvania-based ...

  • Teva Pharmaceutical Industries has completed the previously announced sale of the majority of the assets and operations ...

  • Merck & Co. has decided to advance a clinical development program for which it is partnered with Incyte Corporation, a Wilmington, ...

  • Daiichi Sankyo has formed a partnership in Japan with Kite Pharma, a clinical-stage biopharmaceutical company headquartered ...

  • Kite Pharma, a clinical-stage biopharmaceutical company headquartered in Santa Monica, California, and Shanghai Fosun Pharmaceutical ...

  • Eli Lilly and Company has made a series of changes to its commercial organization and leadership structure. The moves come ...

  • Sanofi and Boehringer Ingelheim (BI) have closed on their previously announced multi-billion dollar business-swap transaction ...